Last updated on November 2017

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment


Brief description of study

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Detailed Study Description

This is a Phase III, randomized, double-blind, placebo-controlled, parallel group, multicenter, efficacy and safety trial of AM-111 in the the treatment of subjects suffering from idiopathic sudden sensorineural hearing loss.

Clinical Study Identifier: TX11313

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sandra Smith

Piedmont Ear, Nose, and Throat Associates
Winston-Salem, NC USA
  Connect »